Huntington's disease: increased number and altered regulation of benzodiazepine receptor complexes in frontal cerebral cortex.
The properties of benzodiazepine receptors in samples of six areas of cerebral cortex from patients and controls matched with respect to age, sex, and postmortem delay have been studied by in vitro radioligand binding techniques. A statistically significant 30 to 40% increase in the number of benzodiazepine and allosterically linked GABA-A receptors is observed in the midfrontal cortex (A9/A10), but in no other cortical region examined. The degree of enhancement of [3H]diazepam binding by a given dose of GABA or pentobarbital is significantly reduced in Huntington's disease midfrontal cortex. As in the case of receptor number changes, other cortical regions examined show less prominent changes in regulation of benzodiazepine binding by GABA or pentobarbital. Direct identification of the benzodiazepine binding subunit by photoaffinity labeling with [3H]flunitrazepam reveals a single species of apparent molecular weight 51 kD in patients and controls, suggesting that gross changes in structure of the benzodiazepine binding subunit do not account for the observed alterations in benzodiazepine receptor regulation.
D003975:Diazepam / Q000378:metabolism; D005625:Frontal Lobe / Q000378:metabolism*; D006801:Humans; D006816:Huntington Disease / Q000378:metabolism*; D011963:Receptors, GABA-A / Q000378:metabolism*
D011963:Receptors, GABA-A; D003975:Diazepam